Bloomberg Intelligence US Manufacturing Activity Contracted in May for a Third Month
18 snips
Jun 2, 2025 The decline in US manufacturing activity raises concerns, driven by tariffs and market instability. Significant pharmaceutical deals highlight the evolving biotech landscape, with Moderna gaining FDA approval for a new Covid vaccine. Investment strategies are examined through the lens of fluctuating markets and the tech sector's impact. The promise of fusion energy and sustainable fuel sources like hydrogen and boron showcases the shift towards cleaner power solutions. Overall, the interplay between manufacturing, healthcare, and energy is explored in depth.
AI Snips
Chapters
Transcript
Episode notes
US Manufacturing Contracts From Tariffs
- US manufacturing contracted for the third month in May due to tariff-induced market uncertainty.
- Lack of new orders and cautious customer inventories reflect subdued demand and production slowdown.
Biotech Deals Rebound in Healthcare
- Healthcare biotech dealmaking slowed by administration policies but is seeing a revival with big pharma acquisitions.
- New cancer drug licenses and biotech deals signal optimism despite regulatory headwinds.
Advancements in Cancer Therapies
- Cancer treatment options are expanding with promising drugs in breast and gastroesophageal cancers.
- Clinical data from AstraZeneca shows practice-changing progress at major oncology conferences.